OPXS Falls 24% in Three Months: Should You Buy the Dip or Wait?

Optex Systems (OPXS) shares fell 23.5% over three months as periscope revenue declined 16.5%, new-customer orders dropped 19.1% to $19.5 million, and backlog fell 21.4% to $30.1 million in the first nine months of fiscal 2026; G&A expenses rose to $5.6 million from $3.6 million. Offsetting risks, recent awards include $2.8 million and $1.2 million laser-filter contracts and a $1.2 million vehicle-support contract, while a $0.4 million infrared-windows award could lead to follow-on orders of up to $14 million annually from Q2 2027 if the program succeeds. The article describes OPXS as undervalued at 1.67X trailing EV/sales versus 11.41X for the industry and recommends buying the dip, while noting defense-program and federal procurement risks.

Analysis

The selloff may be pricing a durable reset in periscope demand, but the apparent EV/sales discount is not a sufficient margin of safety: it compares businesses with different product mixes and says little about OPXS’s ability to convert a shrinking backlog into cash while overhead remains elevated. The more important signal is whether new awards replenish deliveries; delayed procurement can make reported revenue lumpy even without a change in ultimate program demand.

The infrared opportunity is option value, not a near-term earnings anchor. The cited follow-on potential depends on successful execution of a small initial award, and the meaningful delivery window is in 2027. Treating that headline potential as current backlog would overstate visibility. Likewise, HXL and TATT are not clean valuation or operating hedges for OPXS based on the information provided; their multiples do not establish a relative-value trade.

Near term, weak bookings or pricing concessions could compound fixed-cost absorption pressure. Over 1–3 months, the key test is order replenishment and margin trajectory in the next reported results; over 6–18 months, execution on infrared work and resolution of program disruption determine whether the business can diversify. The contrarian case is that new awards and capability investment may be underappreciated, but that case is premature until follow-on demand and conversion are demonstrated. No dip-buy is warranted solely on the peer-multiple discount.

Key Decisions for Investors

• Stay on the sidelines rather than average down immediately. Revisit after the next results show whether bookings stabilize and backlog conversion supports revenue without further margin deterioration.
• Set an alert for two consecutive quarters of book-to-bill above 1 and stable or improving operating margins; treat that as a possible entry signal, not a forecast. Verify these metrics in filings because the article does not provide them.
• Keep the infrared-coating opportunity on a 2027 catalyst watchlist. Do not capitalize the stated annual follow-on potential into a base case until the initial program succeeds and follow-on awards are disclosed.
• Falsify the cautious thesis only if order intake replenishes the pipeline and margins hold; renewed backlog declines, additional cancellations, or guidance deterioration would argue against entry. The eventual M10 resolution remains a longer-dated uncertainty.